Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
Parkinson Study Group PRECEPT Investigators.
Thursday, August 28, 2008
Clinical Trial Results of CEP-1347
Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Daily news on kinase inhibitors.
Labels
- 550 (1)
- Abbott (1)
- Akt (1)
- Amgen (1)
- Angiokinase (1)
- Astellas (1)
- Aurora2 (1)
- Axitinib (1)
- B-Raf (2)
- BMS (2)
- Boehringer Ingelheim (1)
- C-MET (2)
- CAMK2A (1)
- CDK (1)
- CEP-1347 (1)
- Cephalon (2)
- CK1e (1)
- Clinical Trial (10)
- Computational (4)
- CP-690 (1)
- Dasatinib (1)
- Eberhard-Karls-University Tuebingen (1)
- EGFR (1)
- Genentech (1)
- GSK (2)
- GSK3 (1)
- IGF-1R (1)
- IRAK4 (1)
- JAK2 (1)
- JNK (1)
- Lapatinib (1)
- Lck (1)
- Motesanib (1)
- mTOR (1)
- Nilotinib (1)
- p38 (2)
- PDB (3)
- PDK1 (1)
- Pfizer (3)
- Phase II (1)
- PI3K (2)
- Pim1 (1)
- Piramed (1)
- PKA (1)
- PLK (1)
- Plk1 (1)
- Riboxistaurin (1)
- Sorafenib (1)
- Src (1)
- Sunitinib (1)
- Tie1 (1)
- TrkA (1)
- UCB (1)
- University of Florida (1)
- University of Kentucky (1)
- University of Pittsburgh (1)
- University of Rhode Island (1)
Blog Archive
-
►
2009
(1)
- ► 07/05 - 07/12 (1)
-
▼
2008
(32)
- ► 09/07 - 09/14 (3)
- ► 08/31 - 09/07 (10)
-
▼
08/24 - 08/31
(11)
- PDB Update 08/29/08
- Clinical Trial Results of Nilotinib
- Clinical Trial Results of Sunitinib
- Clinical Trial Results of Lapatinib
- Clinical Trial Results of Ruboxistaurin
- Clinical Trial Results of CEP-1347
- Clinical Trial Results of Axitinib
- Clinical Trial Results of Dasatinib
- Clinical Trial Results of Motesanib
- Clinical Trial Results of Sorafenib
- PDB Update 08/26/08
- ► 08/17 - 08/24 (8)
No comments:
Post a Comment